Fluidigm Co. (FLDM) Insider Levin Capital Strategies, L.P. Buys 9,962 Shares

Fluidigm Co. (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. acquired 9,962 shares of the company’s stock in a transaction on Friday, October 26th. The stock was acquired at an average price of $7.20 per share, for a total transaction of $71,726.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Levin Capital Strategies, L.P. also recently made the following trade(s):

  • On Friday, October 19th, Levin Capital Strategies, L.P. acquired 25,209 shares of Fluidigm stock. The stock was acquired at an average price of $7.51 per share, for a total transaction of $189,319.59.
  • On Friday, October 12th, Levin Capital Strategies, L.P. bought 71 shares of Fluidigm stock. The shares were purchased at an average price of $7.44 per share, for a total transaction of $528.24.
  • On Tuesday, October 9th, Levin Capital Strategies, L.P. bought 34,896 shares of Fluidigm stock. The shares were purchased at an average price of $7.29 per share, for a total transaction of $254,391.84.
  • On Monday, October 1st, Levin Capital Strategies, L.P. bought 24 shares of Fluidigm stock. The shares were purchased at an average price of $7.56 per share, for a total transaction of $181.44.
  • On Thursday, September 27th, Levin Capital Strategies, L.P. bought 52 shares of Fluidigm stock. The shares were purchased at an average price of $7.53 per share, for a total transaction of $391.56.
  • On Tuesday, September 25th, Levin Capital Strategies, L.P. bought 2,940 shares of Fluidigm stock. The shares were purchased at an average price of $7.98 per share, for a total transaction of $23,461.20.
  • On Wednesday, September 19th, Levin Capital Strategies, L.P. bought 40 shares of Fluidigm stock. The shares were purchased at an average price of $8.22 per share, for a total transaction of $328.80.
  • On Tuesday, September 11th, Levin Capital Strategies, L.P. bought 17 shares of Fluidigm stock. The shares were purchased at an average price of $8.42 per share, for a total transaction of $143.14.
  • On Thursday, September 6th, Levin Capital Strategies, L.P. bought 201 shares of Fluidigm stock. The shares were purchased at an average price of $7.85 per share, for a total transaction of $1,577.85.
  • On Thursday, August 30th, Levin Capital Strategies, L.P. bought 18 shares of Fluidigm stock. The shares were purchased at an average price of $7.86 per share, for a total transaction of $141.48.

Shares of NASDAQ FLDM opened at $7.21 on Friday. The company has a quick ratio of 1.64, a current ratio of 2.05 and a debt-to-equity ratio of 4.79. Fluidigm Co. has a 1-year low of $4.45 and a 1-year high of $8.62.



Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, August 2nd. The medical research company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.03). The firm had revenue of $26.43 million for the quarter, compared to the consensus estimate of $26.30 million. Fluidigm had a negative return on equity of 104.75% and a negative net margin of 53.65%. As a group, analysts forecast that Fluidigm Co. will post -0.99 earnings per share for the current year.

FLDM has been the topic of a number of recent research reports. Zacks Investment Research lowered Fluidigm from a “buy” rating to a “hold” rating in a research note on Wednesday, July 4th. BidaskClub upgraded Fluidigm from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th.

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its position in Fluidigm by 8.8% during the second quarter. Bank of New York Mellon Corp now owns 433,511 shares of the medical research company’s stock worth $2,585,000 after buying an additional 35,091 shares in the last quarter. Healthcare Value Capital LLC grew its position in Fluidigm by 9.6% during the second quarter. Healthcare Value Capital LLC now owns 450,000 shares of the medical research company’s stock worth $2,682,000 after buying an additional 39,500 shares in the last quarter. LMR Partners LLP acquired a new stake in Fluidigm during the second quarter worth approximately $144,000. Perkins Capital Management Inc. grew its position in Fluidigm by 9.9% during the second quarter. Perkins Capital Management Inc. now owns 169,000 shares of the medical research company’s stock worth $1,007,000 after buying an additional 15,250 shares in the last quarter. Finally, Millennium Management LLC grew its position in Fluidigm by 2,126.0% during the first quarter. Millennium Management LLC now owns 391,249 shares of the medical research company’s stock worth $2,285,000 after buying an additional 373,673 shares in the last quarter. 96.73% of the stock is currently owned by institutional investors and hedge funds.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Read More: Understanding Average Daily Trade Volume

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply